Abstract: Objective :To sum up our clinical experience of treating terminal non-small cell lungcancer by gefitinib (Iressa). Method :Clinical data of 33 patients were collected who received Iressa EAP therapy from Dec.2003 to Feb.2005. Evaluations were made about curative effects, symptoms,quality of life, mean survival time, time to progression and toxic reactions. Results :Total mitigative rateof the focus was 28.1%,total control rate was 62.5%, and alleviative rate of clinical symptoms was63.6%. The difference of KPS grades was significant. Mean survival time of all the patients was 3.3months. Time to progression was 3 months. -grades of toxic reaction were not found. Conclusion :Gefi-tinib is an effective molecule-target curative with good tolerance. It provides a safe and effective wayfor the treatment of recurrent terminal non-small cell lung cancer.